PLK

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

PLK

Polo-like Kinases (PLKs) are a family of highly conserved serine/threonine protein kinases that are essential for a variety of biological functions, including cell division and mitosis checkpoint regulation. Five PLKs (PLK 1-5) play a variety of roles in DNA damage response, intra-S-phase and G2/M checkpoints, spindle formation, and centrosome dynamics in mammals.

PLKs are distinguished by their Polo-box domain, which mediates protein interactions. Depending on the biological context, they are also regulated by transcription, proteolysis, and phosphorylation. PLKs are now understood to function in differentiated cells and link cell division to developmental processes.

PLK related products

Cat No.	Product Name	CAS No.	Product Description
V115339	PLK4-IN-5		PLK4-IN-5 (compound 5f) is a PLK4 inhibitor (IC50 = 0.8 nM).
V115581	PLK4-IN-6		PLK4-IN-6 (compound C05) is a PLK4 inhibitor (IC50 < 0.1 nM).
V110858	PLK4-IN-7		PLK4-IN-7 is a highly selective, orally effective PLK4 inhibitor with an IC50 value of 7.9 nM.
V112503	PMV6-PEG4-BI2536		PMV6-PEG4-BI2536 is a p53-Y220C-PLK1 bifunctional compound consisting of a high-affinity p53-Y220C mutant binder (Kd ≈ 2.5 nM) and a potent PLK1 kinase inhibitor (IC50 = 0.83 nM).
V109335	POI ligand-3		POI ligand-3 (compound 4j) is a peptide PLK1 PBD inhibitor.
V109328	POI ligand-4	1403265-80-4	POI ligand-4 is a PLK1 ligand that can be used to synthesize PROTACs, such as PROTAC PLK1 degrader-3.
V109907	PROTAC PLK1 Degrader-2		PROTAC PLK1 Degrader-2 (compound NC1) is a PLK1 PROTAC degrader with a Kd value of 6.06 μM.
V109994	PROTAC PLK1 Degrader-3	3074520-74-1	PROTAC PLK1 degrader-3 (compound DD-1) is a PLK1 PROTAC degrader based on the N-deglycosylation pathway with a Kd value of 2.2 μM.
V1579	Ro3280 (Ro5203280)	1062243-51-9	RO3280 (also known as Ro-5203280; RO 3280; Ro5203280; RO-3280) is a novel, potent and highly selective inhibitor of Polo-like kinase 1 (PLK1) with potential anticancer activity.
V144376	RP-1664	2980682-00-4	RP-1664 is a highly selective, orally effective PLK4 inhibitor with an IC50 value of 3 nM.
V1581	SBE 13 HCl	1052532-15-6	SBE 13 HCl (SBE13; SBE-13), the hydrochloride salt of SBE13, is a novel, potent and selective Polo-like Kinase 1 (PLK1) inhibitor with potential antineoplastic activity.
V4581	TAK-960	1137868-52-0	TAK-960 (TAK960) is a novel, investigational, orally bioavailable, and selective inhibitor of polo-like kinase 1 (PLK1) with anticancer activity.
V4582	TAK-960 dihydrochloride	1137868-52-0	TAK-960 DiHCl, the dihydrochloride salt of TAK960, is an orally bioavailable, potent, and selective PLK1 polo-like kinase 1 (PLK1) inhibitor with anIC50of 0.8 nM at 10 μM ATP.
V35228	TAK-960 hydrochloride	1137868-96-2	TAK-960 HCl is a potent, orally bioavailable, selective polo-like kinase 1 (PLK1) inhibitor (antagonist) with IC50 of 0.8 nM.
V35229	TAK-960 monohydrochloride	2108449-45-0	TAK-960 mono HCl is a potent, orally bioavailable, selective polo-like kinase 1 (PLK1) inhibitor (antagonist) with IC50 of 0.8 nM.
V104023	TTK/PLK1-IN-1	1817791-70-0	TTK/PLK1-IN-1 (Formula I) is an inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) with IC50 of 7 nM and 72 nM, respectively.
V109917	Y207–5465	667404-66-2	Y207–5465 is a highly effective and selective PLK2 inhibitor with an IC50 value of 584.3 nM.
V79151	YLT-11		YLT-11 is a specific and orally bioactive PLK4 inhibitor (antagonist) with Kds of >10000, 653, >10000 and 5.2 nM for PLK1, PLK2, PLK3 and PLK4 respectively.
V1574	Volasertib (BI 6727)	755038-65-4	Volasertib (formerly also known as BI6727, BI-6727, BI 6727) is a novel and highly potent dihydropteridinone-based Plk1 (polo-like kinase 1) inhibitor with potential antineoplastic activity.
V4268	Rigosertib (ON-01910)	592542-59-1	Rigosertib (formerly also known as ON-01910) is a novel, potent and non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay.